Table 1.
Patient characteristics.
| Characteristics | Number of patients (%) |
|---|---|
| Total Patients | 182 |
| Age (years) | |
| Median | 57.0 |
| Range | 18.8 – 79.5 |
| BMI | |
| Median | 27.8 |
| Range | 14.9 – 48.8 |
| Gender | |
| Male | 112 (61.5%) |
| Female | 70 (38.5%) |
| Histology | |
| Glioblastoma Multiforme | 126 (69.2%) |
| Other Astrocytoma | 33 (18.1%) |
| Oligodendroglioma | 23 (12.6%) |
| IDH Status | |
| Wild Type | 139 (76.4%) |
| Mutant | 43 (23.6%) |
| P53 Status | |
| Wild Type | 163 (89.6%) |
| Mutant | 19 (10.4%) |
| MGMT Status | |
| Wild Type | 162 (89.0%) |
| Methylated | 20 (11.0%) |
| Edema | |
| Present | 101 (55.5%) |
| Absent | 81 (44.5%) |
| Seizures | |
| Present | 115 (63.2%) |
| Absent | 67 (36.8%) |
| Concurrent Temozolomide | |
| Present | 84 (46.2%) |
| Absent | 98 (53.8%) |
| Concurrent Dexamethasone | |
| Present | 50 (27.5%) |
| Absent | 132 (72.5%) |
| Treatment Duration (fractions) | |
| Median | 25 |
| Range | 5 – 33 |
| Follow Up Duration (months) | |
| Median | 16.8 |
| Range | 0.3 – 109.9 |
BMI, Body Mass Index; IDH, Isocitrate Dehydrogenase; MGMT, 06-Methylguanine-DNA Methyltransferase; CI, Confidence Interval.